2017 ACVIM Forum Research Abstract Program

Angiography TTE -Right TTE -Left TEE 3D TEE* MDD 3.0 (1.7-4.9) 4.0 (1.0-8.0) 3.0 (2.-0-4.0) 3.0 (1.0-6.0) A: 2.0 (0.4-3.6) B: 3.0 (0.9-5.8) Ampulla diameter 8.0 (3.2-11.3) 9.0 (4.0-15.0) 9.0 (3.0-12.0) 7.0 (4.0-15.0) A: 5.7 (1.4-8.3) B: 7.6 (2.6-11.8) *Two perpendicular measurements obtained in a cross sectional view addition, chest radiography, echocardiography, and blood pressure measurements were performed depending on the specific cases. Seven of the 9 dogs showed improvements post-treatment, although 2 cases did not show any improvement. ANP levels increased post-treatment in all cases (mean AE standard deviation: pre = 292 AE 163 vs. post = 908 AE 866). NT-proBNP levels increased in 4 cases and decreased in 5 cases (pre = 6563 AE 2061 vs. post = 5627 AE 3026). Aldosterone level increased only in one case (pre = 232 AE 172 vs. post = 124 AE 130) In addition, the left atrial aortic root ratio (LA/Ao), E-wave, vertebral heart score (VHS), and blood pressure decreased. Carperitide is a human ANP agent, which is why we expected higher ANP levels post-treatment. We observed a decrease in NT-proBNP levels in all cases that were treated for more than 7 hours. This is thought to be due to a time lag until the half-life period of NT-proBNP and the stretch stimulation of the ventricular muscle, which are reflected in the blood concentration of NT-proBNP. In addition, the ventricular muscle stretch was inhibited by the decrease in left atrial pressure following the administration of carperitide, which lasted for more than 7 hours. Lastly, the decrease in aldosterone levels was thought to be due to the inhibitory effects of carperitide on the renin-angiotensin-aldosterone system. This study suggested that carperitide administration is effective since pulmonary edema is improved and aldosterone is suppressed.